Ralph Minter is our Chief Scientific Officer and leads our antibody discovery efforts.

Prior to joining Alchemab, Ralph was Senior Director in Antibody Discovery and Protein Engineering at AstraZeneca where he led discovery teams and developed candidate drugs across multiple disease areas. Before joining AstraZeneca, he was part of Cambridge Antibody Technology (CAT), which later became MedImmune.

In addition to antibody discovery, Ralph is known for pioneering new technology platforms within the biologics field, including phenotypic, or target-agnostic, antibody screening which has yielded many novel therapeutic targets, some of which are now being tested in clinical trials.

Ralph earned his PhD in Immunology from Durham University and a BSc in Pathology and Microbiology from Bristol University. He has authored more than 40 papers.